Adaptive Biotechnologies Corporation
1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com
版塊: Healthcare
行業: Biotechnology
全職員工: 709
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman | 1.11M | 232.49k | 1974 |
| Ms. Julie Rubinstein | President & COO | 710.78k | 無 | 1972 |
| Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer | 709.98k | 無 | 1973 |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer | 351.35k | 無 | 1984 |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine | 627.43k | 無 | 1974 |
| Mr. Christopher Carlson Ph.D. | Founder | 無 | 無 | 無 |
| Karina Calzadilla | Vice President of Investor Relations | 無 | 無 | 無 |
| Ms. Stacy L. Taylor | Senior VP, General Counsel & Corporate Secretary | 無 | 無 | 1960 |
| Mr. Francis T. Lo | Chief People Officer | 無 | 無 | 1981 |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD | 無 | 無 | 1982 |
描述
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
公司管治
截至 2024年4月1日 止，Adaptive Biotechnologies Corporation 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：6；董事會：8；股東權利：8；現金賠償：8。
